ClinicalTrials.Veeva

Menu

Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease (SHARP)

University of Wisconsin (UW) logo

University of Wisconsin (UW)

Status and phase

Completed
Phase 2

Conditions

Alzheimer's Disease

Treatments

Drug: Simvastatin
Drug: Placebo

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00939822
H-2008-0275 (Other Identifier)
2015-0038
H-2009-0030 (Other Identifier)
R01AG031790-01A1 (U.S. NIH Grant/Contract)

Details and patient eligibility

About

The purpose of the research is to see how simvastatin affects a substance in the body called beta-amyloid. Beta-amyloid is found in the brain and in the liquid around the brain and spinal cord. High amounts of beta-amyloid may be associated with a greater risk of getting Alzheimer's disease. This study will see if simvastatin can lower the amount of beta-amyloid in the spinal fluid. This study will also see if simvastatin affects memory and thinking, blood flow in the brain, and blood vessel function. The investigators hope that future studies show whether simvastatin might prevent memory loss and decrease the chance of developing Alzheimer's disease.

Full description

Studies show that some medicines that lower cholesterol may reduce the risk of developing Alzheimer's disease, but this has not yet been proven in humans. We are looking for individuals to participate in this study to see if a cholesterol-lowering medication, called simvastatin affects blood flow to the brain, blood vessel function and a substance in the spinal fluid related to the changes in Alzheimer's disease.

The SHARP study included 88 adults ages 40-72 with parental history of documented Alzheimer's disease. The study had 9 visits over the course of 18 months. Participants had fasting blood tests collected, completed a medical history questionnaire and medication side effect review, underwent lumbar puncture procedure, completed memory testing, and had ultrasound and MRI procedures. Participants were randomly assigned to receive either simvastatin or a placebo each night for 18 months.

Enrollment

88 patients

Sex

All

Ages

40 to 72 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Parent diagnosed with Alzheimer's disease
  • Age 40-72

Exclusion criteria

  • Active liver disease
  • History of adverse reaction to statins
  • Contraindication to lumbar puncture
  • Elevated creatine kinase and creatinine lab values
  • Use of medications known to interact with statins
  • History of dementia or mild cognitive impairment
  • Currently pregnant or planning to become pregnant
  • Use of large quantities of grapefruit juice (more than 1 quart per day)
  • Contraindications to MRI (for MRI sub-study)
  • Currently on cholesterol-lowering medication or use in past 4 months
  • History of heart attack, heart problems, stroke and/or diabetes
  • Drinking more than a quart of grapefruit juice per day
  • Metal implants, or metal debris in body (MRI)
  • List of medications that interact with simvastatin

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

88 participants in 2 patient groups, including a placebo group

Simvastatin
Experimental group
Description:
40 mg. Simvastatin/day
Treatment:
Drug: Simvastatin
Placebo
Placebo Comparator group
Description:
Matching Placebo
Treatment:
Drug: Placebo

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems